Since we did not detect any difference in either tumour growth (Fig. 1a) or survival (data not shown) between genotypes at baseline, we proceeded to determine whether CD11c+ cell-specific loss of MK2 would affect tumour progression upon activation of endogenous DCs via delivery of a danger signal. The gene discussed is ITGAX; the disease is neoplasm.